Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Clinical evidence

OP-1250-003

58 evidence topics · 16 sources

Objective
Location and study date
Registry dates and planned enrollment
ItemValue
Study start (actual)“2022-08-31”
Primary completion (estimated)“2027-12-31”
Study completion (estimated)“2028-01-31”
Enrollment (estimated)“190”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using dose-limiting toxicities as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Ribociclib group: participants by cohort, July 2025 data cutoff
CohortParticipants
Dose escalation, palazestrant 30 mg“30 mg (n=3)”
Dose escalation, palazestrant 60 mg“60 mg (n=3)”
Dose escalation, palazestrant 120 mg“120 mg (n=3)”
Dose expansion, palazestrant 90 mg“90 mg (n=16)”
Dose expansion, palazestrant 120 mg“120 mg (n=53)”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Ribociclib group: baseline demographics and disease characteristics, July 2025 data cutoff
CharacteristicPalazestrant 90 mg (n=16)Palazestrant 120 mg (n=56)Total (N=72)
Median age, years (range)“60 (25-76)”“61 (28-85)”“61 (25-85)”
Female sex, n (%)“16 (100%)”“56 (100%)”“72 (100%)”
Premenopausal, n (%)“4 (25%)”“8 (14%)”“12 (17%)”
ECOG performance status 0, n (%)“10 (63%)”“34 (61%)”“44 (61%)”
ECOG performance status 1, n (%)“6 (38%)”“22 (39%)”“28 (39%)”
Measurable disease at baseline, n (%)“12 (75%)”“37 (66%)”“49 (68%)”
Visceral disease, n (%)“6 (38%)”“33 (59%)”“39 (54%)”
No prior line of therapy in the advanced setting, n (%)“10 (63%)”“14 (25%)”“24 (33%)”
One prior line of therapy in the advanced setting, n (%)“5 (31%)”“26 (46%)”“31 (43%)”
Two prior lines of therapy in the advanced setting, n (%)“1 (6.3%)”“12 (21%)”“13 (18%)”
Three prior lines of therapy in the advanced setting, n (%)“0”“4 (7%)”“4 (6%)”
Prior CDK4/6 inhibitor in the advanced setting, n (%)“5 (31%)”“40 (71%)”“45 (63%)”
Prior aromatase inhibitor in the advanced setting, n (%)“5 (31%)”“27 (48%)”“32 (44%)”
Prior fulvestrant in the advanced setting, n (%)“1 (6%)”“22 (39%)”“23 (32%)”
Prior chemotherapy in the advanced setting, n (%)“1 (6.3%)”“10 (18%)”“11 (15%)”
ESR1 mutation at baseline“1/15 (7%)”“14/54 (26%)”“15/69 (22%)”
Efficacy results
Ribociclib group: objective response rate, July 2025 data cutoff
PopulationObjective response rate (n/n)
90 mg cohort (n=12)“42% (5/12)”
120 mg cohort (n=32)“31% (10/32)”
Prior CDK4/6i, 120 mg cohort (n=23)“26% (6/23)”
All (n=44)“34% (15/44)”
Ribociclib group: steady-state ribociclib 600 mg exposure, October 2023 data cutoff
ParameterRibociclib single agentRibociclib in combination with palazestrant
AUC0-24 ([h*ng/mL]/mg), GeoMean (GeoCV); N“23,800 (66%); 54”“25,400 (78%); 8”
Cmax (ng/mL/mg), GeoMean (GeoCV); N“1,820 (62%); 57”“1,860 (66%); 8”
Tmax (h), Median (min–max); N“2.4 (0.68–7.8); 57”“4.0 (1.0–6.0); 8”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Ribociclib group: related treatment-emergent adverse events in at least 25% of participants, n (%)
Event120 mg (n=56), all grades120 mg, grade 3120 mg, grade 490 mg (n=16), all grades90 mg, grade 390 mg, grade 4
Neutropenia (combined term)“47 (84%)”“28 (50%)”“5 (9%)”“13 (81%)”“9 (56%)”“2 (16%)”
Nausea“41 (73%)”“2 (4%)”“0”“11 (69%)”“1 (6%)”“0”
Fatigue“30 (54%)”“3 (5%)”“0”“9 (50%)”“0”“0”
White blood cell decrease“24 (43%)”“9 (16%)”“1 (2%)”“6 (38%)”“4 (25%)”“0”
Diarrhea“24 (43%)”“2 (4%)”“0”“4 (25%)”“0”“0”
Anemia“22 (39%)”“2 (4%)”“0”“5 (31%)”“0”“0”
Vomiting“21 (38%)”“1 (2%)”“0”“4 (25%)”“0”“0”
Electrocardiogram QT prolonged“16 (29%)”“4 (5%)”“0”“4 (25%)”“1 (6%)”“0”
Lymphocyte decrease“16 (29%)”“3 (5%)”“1 (2%)”“3 (19%)”“0”“0”
AST increased“15 (27%)”“2 (4%)”“0”“3 (19%)”“0”“0”
Constipation“15 (27%)”“0”“0”“3 (19%)”“0”“0”
Study limitations
Summary

OP-1250-003 is an open-label phase 1b, 2-part study in 4 treatment groups, and the 2025 presentation cautions that its comparison aggregates results across independent studies and carries the risks inherent in cross-trial comparisons. The ribociclib group population differs from this indication: 24 of 72 participants (33%) had no prior line of therapy in the advanced setting, and 45 (63%) had received a prior CDK4/6 inhibitor. Cohorts include 16 participants at palazestrant 90 mg and 56 at 120 mg, and response rates are based on 12 and 32 response-evaluable participants, respectively. The presentation describes efficacy as “maturing”: 30 of 72 participants (42%) remained on treatment at the July 8, 2025 cutoff, and median PFS in the 90 mg cohort was not reached at a median follow-up of 10.8 months. Responses were assessed by the investigator, and the analysis presented 72 of 78 enrolled participants. Interim results were reported at successive cutoffs (March 13, 2024; September 25, 2024; and July 8, 2025) with different analysis populations.